May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Mortality in the Age-Related Eye Disease Study: Associations With Age-Related Macular Degeneration (AMD)
Author Affiliations & Notes
  • S. Bressler
    Wilmer Eye Institute, Baltimore, MD, United States
  • N.M. Bressler
    Wilmer Eye Institute, Baltimore, MD, United States
  • S.R. Chandra
    Department of Ophthalmology & Visual Sciences, University of Wisconsin, Madison, WI, United States
  • E.Y. Chew
    National Institutes of Health, National Eye Institute, Bethesda, MD, United States
  • T.E. Clemons
    EMMES Corporation, Rockville, MD, United States
  • R. Klein
    University of Wisconsin, Dept. of Ophthalmology & Visual Sciences, Madison, WI, United States
  • J.M. Seddon
    Massachusetts Eye and Ear Infirmary, Boston, MA, United States
  • AREDS Research Group
    Massachusetts Eye and Ear Infirmary, Boston, MA, United States
  • Footnotes
    Commercial Relationships  S. Bressler, None; N.M. Bressler, None; S.R. Chandra, None; E.Y. Chew, None; T.E. Clemons, None; R. Klein, None; J.M. Seddon, None.
  • Footnotes
    Support  Supported by contracts from NEI/NIH; additional support from Bausch & Lomb, Inc.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2056. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Bressler, N.M. Bressler, S.R. Chandra, E.Y. Chew, T.E. Clemons, R. Klein, J.M. Seddon, AREDS Research Group; Mortality in the Age-Related Eye Disease Study: Associations With Age-Related Macular Degeneration (AMD) . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2056.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To assess retrospectively whether advanced AMD is associated with mortality among participants in the Age-Related Eye Disease Study (AREDS), a randomized clinical trial of AMD and lens opacity. Methods: Stereoscopic color fundus photographs taken at baseline and graded at a reading center were used to enroll AREDS participants into one of four AMD categories. Category 1 - Few if any small drusen; Category 2 - Extensive small drusen or at least 1 medium size druse; Category 3 - Extensive medium size drusen or at least 1 large druse; and Category 4 - Advanced AMD in one eye. Median follow-up was 6.5 years. The primary outcome for this report was all-cause mortality. Analyses of cause-specific mortality, based on ICD-9 codes, were also performed. Covariate-adjusted (i.e., age, gender, race, education, smoking, BMI, diabetes, angina, cancer and hypertension) Cox-proportional hazards models were created with AMD category at baseline as the independent variable. Results: Between 1993 and 2001, 507 (11%) of the 4,753 participants (age 55 to 81 years [mean 69 years]) with follow-up data died. All-cause mortality increased with worsening macular pathology. Participants with late AMD in one eye (Category 4) compared to participants with few if any drusen (Category 1) had a significantly increased risk of mortality (RR 1.41; 95% CI: 1.06, 1.86). Significant associations were not found for AMD Category 2 (RR=1.06) or AMD Category 3 (RR=1.11). Advanced AMD remained a significant predictor of mortality in models accounting for lens opacities or cataract surgery. In analyses of cause-specific mortality, advanced AMD in one eye (RR 1.87; 95% CI: 1.13, 3.08) was associated with an increased risk of cardiovascular deaths. Results from analyses considering potential AREDS treatment effect remain consistent. Conclusions: All-cause mortality was increased among AREDS participants who had advanced AMD in one eye. No associations with all-cause mortality were noted for persons with less severe age-related macular abnormalities (Categories 2 or 3). Persons with advanced AMD were at increased risk of death from cardiovascular disease. The relation of these statistical associations to cause and effect is unknown.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: pre • clinical (human) or epidemiologic studies: ris 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.